Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • amyloid

    - PMLiVE

    Breakthrough Alzheimer’s Therapies Drive Early Detection Rates While Exposing Deep Treatment Disparities

    Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in detection for women and treatment access for Black...

    Medscape Education

    - PMLiVE

    Lilly launches global Alzheimer’s campaign with Julianne Moore

    The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

    Biogen Idec building

    Rolling submission granted for Biogen/Eisai’s next Alzheimer’s antibody

    The FDA will review the data for Biogen and Eisai’s anti-amyloid beta protofibril antibody, lecanemab, on an ongoing basis

    Biogen Idec building

    Embattled Biogen talks up Aduhelm

    Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm

    - PMLiVE

    Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm

    Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company.

    - PMLiVE

    Lilly restructures in preparation for Alzheimer’s drug launch

    As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

    - PMLiVE

    Lilly restructures in preparation for Alzheimer’s drug launch

    As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

    Article

    A glimmer of hope for Alzheimer’s patients, but at what cost?

    Inizio

    - PMLiVE

    Merck gets Alzheimer’s label claim for insomnia drug Belsomra

    Alzheimer's patients typically experience poor sleep

    - PMLiVE

    Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

    Gained conditional approval in China in November

    Are we ready for an Alzheimer’s disease modifying treatment

    Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. But if a new therapy entered the market today, would healthcare systems be ready for...

    Blue Latitude Health

    - PMLiVE

    Biogen and Eisai drop Alzheimer’s drug elenbecestat

    Latest blow in string of failures for BACE inhibitor category

    2025 T40 open for submissions
    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links